ASH
Ashland Inc.58.65
-1.18-1.97%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.68BP/E (TTM)
-Basic EPS (TTM)
-17.74Dividend Yield
0.03%Recent Filings
10-K
8-K
8-K
Director Pedreiro resigns
Ashland Inc. announced the resignation of board director Sergio Pedreiro, effective September 30, 2025, including his seats on the Compensation Committee and as Audit Committee Chair. The board size shrinks from nine to eight members. No disagreements with company practices prompted the move. This shift trims oversight depth amid steady operations.
10-Q
Q3 FY2025 results
Ashland's Q3 FY2025 sales fell 15% y/y to $463M, driven by divestitures like Avoca and lower volumes across segments, while gross margin contracted to 28.5% from 34.2% amid higher operating costs and accelerated depreciation for manufacturing optimizations. Operating loss widened sharply to $708M from $61M, fueled by a $706M non-cash goodwill impairment in Life Sciences and Specialty Additives reporting units, yet underlying adjusted EBITDA held at $113M, down 19% y/y but buoyed by cost reductions. YTD, sales dropped 15% to $1,347M with operating loss at $836M versus $57M, as portfolio shifts trimmed revenue by $170M but improved margins slightly to 29.0%. Cash dipped to $207M, with $94M operating cash flow funding $64M capex and $100M stock repurchases; free cash flow (derived) came in at $30M, while $596M revolver availability supports liquidity amid $1.4B debt at 2.9x net leverage. The Avoca sale closed in March 2025 for $16M net proceeds, recognizing $183M impairment but no goodwill or intangibles details beyond allocation. Ongoing asbestos litigation poses persistent risks, with reserves at $450M and open claims steady at 52.
8-K
Ashland Q3 sales drop 15%
Ashland reported third-quarter fiscal 2025 sales of $463 million, down 15% year-over-year, with portfolio optimization initiatives slashing $53 million from the top line. A $706 million non-cash goodwill impairment drove a $719 million loss from continuing operations, yet adjusted EBITDA held at $113 million, buoyed by cost discipline amid softer demand. The company narrowed its full-year outlook to $1.825-$1.850 billion in sales and $400-$410 million in adjusted EBITDA. Operational resilience shines through.
IPO
Website
Employees
Sector
Industry
APD
Air Products and Chemicals, Inc
242.25-2.76
AVNT
Avient Corporation
30.50+0.02
BCPC
Balchem Corporation
157.10-1.61
BON
Bon Natural Life Limited
1.79+0.04
CC
Chemours Company (The)
11.69-0.09
DD
DuPont de Nemours, Inc.
40.45-0.16
EMN
Eastman Chemical Company
63.65-0.30
IFF
International Flavors & Fragran
64.58+0.41
LNXSF
Lanxess Ag
20.00+0.00
MATV
Mativ Holdings, Inc.
12.82+0.09